Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs.

Abstract

BACKGROUND:

Oclacitinib administered at the licensed dose twice daily for two weeks and then once daily as required is recommended for the treatment of atopic dogs. In some cases, the once-daily regimen is insufficient to control the clinical signs.

OBJECTIVES:

To provide preliminary safety and efficacy data on the prolonged twice-daily administration of oclacitinib in atopic dogs.

ANIMALS:

Fifty-three client-owned atopic dogs.

METHODS AND MATERIALS:

The medical records of dogs with atopic dermatitis treated with oclacitinib twice daily for more than two weeks were reviewed retrospectively. Animal details, treatment dose and duration, concurrent diseases, adjunctive medications and possible adverse events were recorded. Treatment efficacy was assessed retrospectively and, when available, the selected blood parameters before and during the treatment were compared. Statistical analyses of the collected data were performed.

RESULTS:

The median treatment duration was 113 days. Excellent-to-good efficacy was observed in 38 dogs (72%), including 24 of 33 dogs that failed to respond to the once-daily regimen. Eight dogs showed a poor response despite the addition of systemic glucocorticoids. Pyoderma, gastrointestinal signs and otitis externa were the most frequent adverse events recorded whilst on treatment. Blood tests performed in 35 dogs showed slightly decreased leucocyte, neutrophil, eosinophil and monocyte counts that remained within the reference ranges in most cases. Three dogs developed hypercholesterolemia.

CONCLUSIONS AND CLINICAL RELEVANCE:

Prolonged twice-daily administration of oclacitinib generally was well-tolerated and was effective in most of the treated dogs. Regular clinical evaluation and blood tests are advisable for this treatment regimen.

• Authors: Daria Denti, Marco Caldin, Laura Ventura, Michela De Lucia
• Journal: Veterinary dermatology (Vet Dermatol) Vol. 33 Issue 2 Pg. 149-e42 (Apr 2022) ISSN: 1365-3164 [Electronic] England
• PMID: 35014745 (Publication Type: Journal Article)
• Copyright: © 2022 ESVD and ACVD.

Chemical References

• Dermatologic Agents
• Pyrimidines
• Sulfonamides
• oclacitinib

Topics

• Animals
• Dermatitis, Atopic (drug therapy, veterinary)
• Dermatologic Agents
• Dog Diseases (chemically induced, drug therapy)
• Dogs
• Pyrimidines
• Retrospective Studies
• Sulfonamides